'You've Just Got to Keep Pestering': Barriers and Enablers of Attaining Continuity of Hepatitis C Care for People Transitioning Between Prison and Community Health Services in South-East Queensland, Australia.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Hepatitis C*/drug therapy ; Hepatitis C*/therapy ; Continuity of Patient Care* ; Community Health Services* ; Prisons* ; Prisoners*; Humans ; Queensland ; Male ; Female ; Adult ; Middle Aged ; Qualitative Research ; Antiviral Agents/therapeutic use ; Health Services Accessibility

Highly effective direct-acting antiviral (DAA) therapies for hepatitis C (HCV) have been available in Australian prisons since 2016. To address treatment interruption following release from prisons, the Queensland Injector's Health Network (QuIHN) launched a Prison Transition Service (PTS) in south-east Queensland, Australia. Presently, the factors associated with continuity of post-release HCV care are poorly understood. The objective of this qualitative study was to explore the barriers and facilitators to HCV treatment among people recently released from prisons among PTS clients and stakeholders. Qualitative interviews were conducted with 27 participants, namely, 13 clients and 14 stakeholders (health and community support workers) of the PTS. We conducted thematic analysis using the framework of person-, provider-, and system-level barriers and facilitators. Person-level barriers included competing priorities post-release, while facilitators included self-improvement after treatment completion, preventing transmission to family, and social support. Provider-level treatment barriers included enacted stigma, limited prison health service capacity, and post-release health system challenges. Systemic barriers included stigma relating to HCV, injecting drug use, incarceration, and limited availability of harm reduction services. Policy changes and investment are required to expand HCV treatment in south-east Queensland prisons to facilitate patient navigation into community care. In terms of reducing stigma among health staff and the general community towards people with HCV, a history of incarceration and/or who inject drugs is crucial for improving treatment rates. Strategies such as peer-led or nurse-practitioner-led models of care may help improve treatment completion. Continuity of HCV treatment post-release from prisons is essential for Australia to meet the WHO's 2030 HCV elimination target.

Viruses. 2022 Feb 28;14(3):. (PMID: 35336905)
Drug Alcohol Depend. 2023 Dec 1;253:111013. (PMID: 37951006)
Drug Alcohol Depend. 2021 Oct 1;227:108970. (PMID: 34488074)
Aust N Z J Public Health. 2008 Feb;32(1):86-7. (PMID: 18290920)
AIDS Behav. 2009 Dec;13(6):1160-77. (PMID: 19636699)
Aust N Z J Public Health. 2007 Dec;31(6):540-4. (PMID: 18081574)
Subst Use Misuse. 2021;56(2):175-184. (PMID: 33208025)
Med J Aust. 2023 Mar 20;218(5):231-237. (PMID: 36871200)
Clin Infect Dis. 2024 Sep 16;:. (PMID: 39282957)
Ethn Health. 2016;21(1):39-57. (PMID: 25665723)
Addiction. 2017 Jul;112(7):1302-1314. (PMID: 28257600)
Open Forum Infect Dis. 2022 Jul 28;9(8):ofac350. (PMID: 35949401)
Am J Prev Med. 2023 Dec;65(6):1153-1162. (PMID: 37380088)
Crim Behav Ment Health. 2024 Feb;34(1):79-93. (PMID: 38212591)
Aust J Prim Health. 2022 Jun;28(3):239-246. (PMID: 35135655)
Int J Drug Policy. 2024 Nov;133:104624. (PMID: 39426103)
Int J Drug Policy. 2022 Jan;99:103455. (PMID: 34560625)
J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v17-v23. (PMID: 31782500)
J Health Care Poor Underserved. 2018;29(4):1544-1557. (PMID: 30449762)
Soc Sci Med. 2016 Oct;167:29-36. (PMID: 27597539)
J Viral Hepat. 2018 Dec;25(12):1526-1532. (PMID: 30141261)
J Gen Intern Med. 2003 Oct;18(10):835-44. (PMID: 14521647)
J Hepatol. 2019 May;70(5):839-846. (PMID: 30654067)
Lancet. 2015 Jul 25;386(9991):350-9. (PMID: 26028120)
Int J Drug Policy. 2020 Mar;77:102693. (PMID: 32045828)
Soc Sci Med. 2013 Apr;83:19-26. (PMID: 23465200)
Lancet Reg Health West Pac. 2024 Nov 21;53:101240. (PMID: 39633715)
J Viral Hepat. 2023 Apr;30(4):278-282. (PMID: 36636765)
Health Expect. 2024 Feb;27(1):e13908. (PMID: 37920874)
Soc Sci Med. 2003 Apr;56(7):1453-68. (PMID: 12614697)
J Viral Hepat. 2020 Feb;27(2):205-220. (PMID: 31638294)
Int J Drug Policy. 2024 Dec;134:104628. (PMID: 39471757)
Soc Sci Med. 2003 Jul;57(1):13-24. (PMID: 12753813)
Expert Rev Mol Diagn. 2017 Dec;17(12):1109-1115. (PMID: 29088981)
Int J Cancer. 2018 Jun 15;142(12):2471-2477. (PMID: 29388206)
Am J Gastroenterol. 2018 Nov;113(11):1639-1648. (PMID: 29946175)
Int J Drug Policy. 2019 Oct;72:123-128. (PMID: 30967329)
J Viral Hepat. 2016 Jun;23(6):473-8. (PMID: 26856967)
Addiction. 2020 May;115(5):914-915. (PMID: 32026531)
J Hepatol. 2017 Aug;67(2):263-271. (PMID: 28412293)
Psychol Health Med. 2006 Aug;11(3):335-45. (PMID: 17130069)
BMC Med. 2019 Feb 15;17(1):7. (PMID: 30764816)
Int J Drug Policy. 2020 Jan;75:102608. (PMID: 31759307)
Int J Drug Policy. 2024 Jul;129:104461. (PMID: 38971019)
Clin Infect Dis. 2018 Jul 18;67(3):460-463. (PMID: 29538639)
Harm Reduct J. 2018 Aug 3;15(1):39. (PMID: 30075728)
World J Gastroenterol. 2018 Nov 28;24(44):4959-4961. (PMID: 30510370)
AIDS. 2009 Nov 13;23(17):2353-7. (PMID: 19741478)
Int J Drug Policy. 2020 Jun;80:102532. (PMID: 31427211)
Harm Reduct J. 2019 Jul 5;16(1):42. (PMID: 31277665)
Drug Alcohol Depend. 2016 Nov 01;168:104-111. (PMID: 27635997)
PLoS One. 2016 Sep 09;11(9):e0162399. (PMID: 27611849)

Keywords: health services for prisoners; hepatitis C; prisons; qualitative research; social stigma

0 (Antiviral Agents)

Date Created: 20250226 Date Completed: 20250510 Latest Revision: 20250510

20250510

PMC11855011

10.3390/ijerph22020238

40003464